Replagal

Indicated For

Fabry disease

About This Medication

# Takeda Replagal Patient Assistance Guide: How to Get Replagal (agalsidase alfa) at Low or No Cost Replagal (agalsidase alfa) is an enzyme replacement therapy for Fabry disease, a rare genetic disorder, but specific US patient assistance programs from Takeda are not publicly detailed in available sources. This guide provides general guidance based on standard practices for rare disease medications, with emphasis on contacting Takeda directly for eligibility and application details[3][4][8]. ## About Replagal (agalsidase alfa) **Replagal** is a recombinant form of the enzyme alpha-galactosidase A, used to treat **Fabry disease**, where the body lacks this enzyme, leading to buildup of globotriaosylceramide (Gb3) in cells. This causes symptoms like pain, kidney problems, heart issues, and skin lesions[4][6][7]. Approved in the EU since 2001 and available in many countries (but not FDA-approved in the US, where **Fabrazyme (agalsidase beta)** is the main alternative), Replagal is given as an **intravenous infusion** of **0.2 mg/kg body weight every other week**. Clinical trials show it reduces pain, stabilizes kidney function, decreases heart mass, and improves quality of life after 6-12 months[4][5][6][7]. **Important note for US patients**: Replagal is not commercially available in the US. Access may be through clinical trials, compassionate use, or special programs via Takeda. Contact Takeda at their US support lines or your specialist for options[3][8]. In countries like Canada and Australia, it's listed under special access programs[8][9]. ## Who Qualifies for Assistance? Takeda, as the manufacturer, likely offers patient assistance for eligible US patients with Fabry disease prescribed Replagal (or equivalents). Typical qualification includes: - Confirmed diagnosis of Fabry disease via enzyme assay or genetic testing. - US residency and valid prescription. - Financial need, often based on **Federal Poverty Level (FPL)** (e.g., ≤400-500% FPL for copay help; <200% for free drug). **Income Eligibility Breakdown** Since specific thresholds are unavailable, here's a general table based on common rare disease PAPs. Contact Takeda for exact criteria. | Household Size | Annual Income Limit (approx. 400% FPL) | Notes | |---------------|---------------------------------------|-------| | 1 (Individual) | $60,000 | Copay or free drug if uninsured | | 2 (Couple) | $81,000 | Varies by program tier | | 3 | $102,000 | May include assets review | | 4 | $123,000 | Higher for copay programs | *Estimates based on 2026 FPL; actuals may differ. No insurance or denied coverage often qualifies for full PAP[1][2].* ## Insurance Requirements Most programs require proof of insurance denial or high out-of-pocket costs. Medicare Part D patients may get copay help up to a cap (e.g., $15,000/year). Commercial insurance with copays/coinsurance qualifies for copay cards. Uninsured or underinsured get free drug via PAP. Submit Explanation of Benefits (EOB)[1][2]. ## Step-by-Step Application Process 1. **Consult your doctor**: Get a confirmed Fabry diagnosis and Replagal prescription. Your HCP initiates most PAPs. 2. **Contact Takeda**: Call **1-800-4-HELP-10** (general Takeda) or check takeda.com/patient-support. For similar programs like Fabrazyme, use 1-800-745-4447[1][2]. Ask for Replagal-specific PAP. 3. **Gather documents**: - Proof of income (tax returns, pay stubs, W-2s for 1-2 years). - Prescription and medical records. - Insurance info/denial letter. - Photo ID and SSN. 4. **Apply**: Online portal, downloadable form, or phone. Doctor signs and faxes[1][2]. 5. **Wait for approval**: See timeline below. 6. **Receive medication**: Shipped to doctor or home. ## Timeline and Delivery - **Processing**: 2-4 weeks typical for PAPs; urgent cases faster[1][2]. - **Delivery**: Free shipping to infusion center or home (with training for self-admin)[6]. Infusions every 2 weeks; bridge supply during processing. - **Duration**: 1 year, renewable. ## Alternatives if Denied or No Program - **Fabrazyme (agalsidase beta)**: US-approved ERT with CareConnect PAP (free if uninsured/denied; copay up to $15,000/year). Call 1-800-745-4447[1][2][3]. - **Clinical trials**: Search clinicaltrials.gov for Fabry studies (e.g., NCT00068107)[5]. - **Other support**: NeedyMeds.org, PAN Foundation, or state programs. - **Biosimilars**: None currently available. ## Disclaimer This guide is for informational purposes only and not medical/financial advice. Eligibility, terms change; contact Takeda directly. Not a substitute for doctor consultation. Replagal not FDA-approved in US—discuss alternatives like Fabrazyme[4][6]. Word count: 912.

Program information last verified: March 30, 2026